169 research outputs found
Characterization of cell-free protein-synthesis systems from undeveloped and developing Artemia embryos
In Vivo Confirmation of the Role of Statins in Reducing Nitric Oxide and C-Reactive Protein Levels in Peripheral Arterial Disease
AbstractObjectivesInflammatory and other processes mediating impairment of endothelial function, where there are increased levels of C-reactive protein (CRP) and plasma nitrites, have a part to play in the early stages of peripheral arterial disease (PAD). Our objective was to analyse the effect of statins on the plasma nitrite and CRP levels in PAD.Material and methodsA prospective study of 30 patients with PAD Fontaine stage II, with no prior treatment with statins, determined high sensitivity (hs)-CRP and lipid profile in the patients. Plasma nitrite levels were determined by colourimetric assay based on the Griess reaction, at baseline and after 1 month of treatment with atorvastatin 40mgdayâ1.ResultsA significant reduction in plasma nitrite levels was detected after the treatment with statins (11.88±7.8ÎŒM vs. 5.7±1.8ÎŒM, p=0.0001). There was also a significant reduction in hs-CRP levels (13.58±24.00 vs. 3.93±3.19, p=0.02).When the patients were stratified according to claudication stage, a significant reduction in nitrite levels was obtained, both in patients with PAD Fontaine stage IIA (9.5±3.3ÎŒM vs. 5.3±1.7ÎŒM, p=0.0001) and in stage IIB (16.6±11.6ÎŒM vs. 6.7±1.8ÎŒM, p=0.032).ConclusionsTreatment with statins lowers plasma nitrite and CRP levels in patients with PAD. Our data support the effects of statins in vivo that have been demonstrated on the endothelium ex vivo, suggesting a beneficial effect by acting on the initial processes that trigger the disease, reducing oxidative stress (increase in the bioavailability of nitric oxide as peroxynitrite levels decrease) and curtailing the inflammatory processes which perpetuate the disease
Binary Planetary Nebulae Nuclei towards the Galactic Bulge. I. Sample Discovery, Period Distribution and Binary Fraction
Binarity has been hypothesised to play an important, if not ubiquitous, role
in the formation of planetary nebulae (PNe). Yet there remains a severe paucity
of known binary central stars required to test the binary hypothesis and to
place strong constraints on the physics of the common-envelope (CE) phase of
binary stellar evolution. Large photometric surveys offer an unrivalled
opportunity to efficiently discover many binary central stars. We have combined
photometry from the OGLE microlensing survey with the largest sample of PNe
towards the Galactic Bulge to systematically search for new binaries. A total
of 21 periodic binaries were found thereby more than doubling the known sample.
The orbital period distribution was found to be best described by CE population
synthesis models when no correlation between primary and secondary masses is
assumed for the initial mass ratio distribution. A comparison with post-CE
white dwarf binaries indicates both distributions are representative of the
true post-CE period distribution with most binaries exhibiting periods less
than one day. An estimated close binary fraction of 12--21% is derived and is
the first robust and independent validation of the prevailing 10--15% fraction
estimated by Bond (2000). This suggests that binarity is not a precondition for
the formation of PNe and that close binaries do not play a dominant role in the
shaping of nebular morphologies. Systematic effects and biases of the survey
are discussed with implications for future photometric surveys.Comment: Accepted for publication in A&
Validated spectrophotometric methods for determination of Alendronate sodium in tablets through nucleophilic aromatic substitution reactions
<p>Abstract</p> <p>Background</p> <p>Alendronate (ALD) is a member of the bisphosphonate family which is used for the treatment of osteoporosis, bone metastasis, Paget's disease, hypocalcaemia associated with malignancy and other conditions that feature bone fragility. ALD is a non-chromophoric compound so its determination by conventional spectrophotometric methods is not possible. So two derivatization reactions were proposed for determination of ALD through the reaction with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) and 2,4-dinitrofluorobenzene (DNFB) as chromogenic derivatizing reagents.</p> <p>Results</p> <p>Three simple and sensitive spectrophotometric methods are described for the determination of ALD. Method I is based on the reaction of ALD with NBD-Cl. Method II involved heat-catalyzed derivatization of ALD with DNFB, while, Method III is based on micellar-catalyzed reaction of the studied drug with DNFB at room temperature. The reactions products were measured at 472, 378 and 374 nm, for methods I, II and III, respectively. Beer's law was obeyed over the concentration ranges of 1.0-20.0, 4.0-40.0 and 1.5-30.0 Όg/mL with lower limits of detection of 0.09, 1.06 and 0.06 Όg/mL for Methods I, II and III, respectively. The proposed methods were applied for quantitation of the studied drug in its pure form with mean percentage recoveries of 100.47 ± 1.12, 100.17 ± 1.21 and 99.23 ± 1.26 for Methods I, II and III, respectively. Moreover the proposed methods were successfully applied for determination of ALD in different tablets. Proposals of the reactions pathways have been postulated.</p> <p>Conclusion</p> <p>The proposed spectrophotometric methods provided sensitive, specific and inexpensive analytical procedures for determination of the non-chromophoric drug alendronate either per se or in its tablet dosage forms without interference from common excipients.</p> <p>Graphical abstract</p> <p><display-formula><graphic file="1752-153X-6-25-i3.gif"/></display-formula></p
CIBERER : Spanish national network for research on rare diseases: A highly productive collaborative initiative
Altres ajuts: Instituto de Salud Carlos III (ISCIII); Ministerio de Ciencia e Innovación.CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low-prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15-year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research
- âŠ